Eiger BioPharmaceuticals, Inc.
EIGR
Classificação em ações
#36385
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preço da ação
$1.73
Última sincronização: 2025-06-17
Valor de mercado
$2.55M
Variação (1 dia)
-0.29%
Variação (1 ano)
-79.71%
País
US
Negociar Eiger BioPharmaceuticals, Inc. (EIGR)
Categoria
Healthcare
Histórico de preços das ações de Eiger BioPharmaceuticals, Inc. (EIGR)
Preço de fecho mais alto: $8.50 em 2024-10-01
Preço de fecho mais baixo: $3.75K em 2014-01-01
Preço de fecho mais baixo: $3.75K em 2014-01-01
Histórico de preços das ações da Eiger BioPharmaceuticals, Inc. de 2014 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2024 | 8.23% |
| 2023 | -86.28% |
| 2022 | -65.86% |
| 2021 | -43.34% |
| 2020 | -27.82% |
| 2019 | 28.55% |
| 2018 | -15.78% |
| 2017 | 8.44% |
| 2016 | -45.90% |
| 2015 | -91.44% |
| 2014 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
